Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tandem Diabetes Care (TNDM – Research Report), Lemai...

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Lemaitre Vascular (LMAT) and Shattuck Labs (STTK)

Shattuck Labs, Inc. ( ($STTK) ) has released its Q3 earnings. Here is a breakdown of the information Shattuck Labs, Inc. presented to its investors...

Current Quarter	$-0.12	Next Quarter	$-0.1
Current Year	$-0.7	Next Year	$-0.42
QoQ Growth	+16.7%	YoY Growth	+40.0%
3Y EPS CAGR	-11.7%	Target Price	$2.64
Consensus	Buy	Upside	+30.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STTK	$2.03	+5.18%	93.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	STTK	$2.03	+5.2%	93.71K
3
4
5
6

STTK

STTK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Shattuck Labs Inc. Data in Excel

Get Shattuck Labs Inc. Data in Excel